Articles tagged with Immunotherapy
Researchers have identified a secreted form of a protein called Clever-1 that systemically suppresses T cells essential for fighting cancer. The investigational anti-Clever-1 antibody, bexmarilimab, directly inhibits the release of sClever-1, potentially predicting treatment resistance and paving the way for new combination treatments.
Research has shown that lymph nodes provide the right environment for stem-like T cells to survive, multiply, and produce killer cells. Preserving lymph nodes could strengthen immune responses and increase the effectiveness of immunotherapy. The study's findings have important implications for cancer therapy.
Researchers are developing a novel smart coating to enable continuous monitoring of cells during CAR T-cell production, reducing production costs. The biosensor coating is expected to reduce human errors and costs associated with existing flow cytometry methods.
Researchers have found a way to use antibodies to direct T cells to kill Cytomegalovirus-infected cells, offering an alternative treatment for life-threatening infections without expensive and side-effect-prone drugs.
Researchers at UMass Amherst found that certain T-cells have an inherent ability to remember past viral foes, which could lead to next-generation cancer vaccines. This 'immunological memory' is crucial for the body's immune response and can be harnessed for targeted therapies.
Researchers at NUS have developed a bioengineering approach to keep human lymph node tissue alive and functioning outside the body for several days. The method involves embedding thin slices of lymph node tissue in a soft gel that mimics the body's natural environment, allowing for detailed studies of immune cell behavior.
Research by University of Pittsburgh scientists discovered that damaging telomeres can lead to dysfunctional T cell function. To combat this, they developed a targeted antioxidant approach that rescued T cell function, opening the door for novel therapies in cancer immunotherapies.
Adult fibrosarcoma is a rare and highly aggressive malignancy requiring precise diagnosis and multimodal treatment. The case report emphasizes the need for early detection, complete surgical removal, and tailored postoperative care to improve outcomes in patients with this type of tumor.
Researchers harness AlphaFold 3 to predict how T cells recognize peptides, opening avenues for precision immunotherapy and vaccine design. The approach enables in silico identification of immunogenic epitopes that could serve as vaccine targets.
Researchers have identified a potential new strategy for treating glioblastoma multiforme (GBM), the most common and aggressive type of adult brain cancer. Disabling a protein called ADAR1 can stall GBM cell proliferation while reprogramming the tumor microenvironment to an anti-tumoral state.
A new mitochondrial-targeting drug, LCL768, has been developed to attack head and neck cancer cells by damaging their mitochondria. The drug's ability to increase ceramide levels inside mitochondria triggers mitophagy, leading to cancer cell death.
Researchers have developed AlloCAR70-NKT, an innovative cell therapy harnessing the immune system to fight cancer. The therapy demonstrates a multi-pronged attack against kidney cancer, directly killing cells and disrupting the tumor's microenvironment.
Researchers at Lund University identify genetic toolkit to program dendritic cell subtypes for targeted cancer treatment. The discovery could lead to more precise and powerful immunotherapies by supplying patients with tailored dendritic cells.
A phase 2 clinical trial found that autologous tumor-infiltrating lymphocyte (TIL) cell therapy helped stabilize metastatic head and neck squamous cell carcinoma (HNSCC) in some patients. The median response duration was 7.6 months, with cancer stabilization occurring in 64% of patients.
A new study by Moffitt Cancer Center researchers has found that cancer-induced nerve injury weakens the effectiveness of anti-PD-1 immunotherapy. The study shows that cancer cells infiltrate and damage tumor-associated nerves, triggering an inflammatory response that ultimately suppresses the immune system's ability to fight cancer.
Researchers found that cancer cells break down nerve protective covers, triggering chronic inflammation and immune exhaustion, making treatment resistant. Targeting the nerve injury pathway can reverse this resistance and improve treatment response.
A new study from Moffitt Cancer Center found that a combination of immune-targeting drugs, including TIM-3, was effective in shrinking tumors in lab models of treatment-resistant melanoma. The triplet therapy also restored immune function and led to complete tumor regressions in some cases.
A new blood test, PIPscore, has been developed to predict the efficacy of immunotherapy in triple-negative breast cancer (TNBC) patients. The test analyzes plasma proteins and achieved high accuracy in forecasting patient responses.
Researchers developed a neoAg mRNA-based vaccine that induces higher frequency of neoAg-specific cytotoxic T cells in mice, leading to tumor regression and eradication. The combination with anti-PD-1 therapy enhances antitumor efficacy, especially against peritoneal metastasis.
A team of researchers developed a technology that allows them to measure millions of cell-to-cell interactions quickly and affordably. The study shows that this approach can help predict how patients will respond to immunotherapies, laying the foundation for more personalized treatments.
A study by Zhejiang University reveals how IL-6 reprograms PD-L1 expression in colorectal cancer stem cells, driving immunosuppressive effects. Dual-target therapy combining PI3K and STAT3 inhibitors shows promise in overcoming immunotherapy resistance.
A study of 107 patients found that starting immunotherapy as early as possible can halt the progression of anti-IgLON5 disease, with intravenous immunoglobulins showing superior results. The average age at diagnosis was 64 years, but only one-third of patients were diagnosed within a year of symptoms.
A new deep learning model, MSI-SEER, achieves high accuracy in predicting microsatellite instability-high tumors and their responsiveness to immunotherapy. The model combines tumor MSI status with stroma-to-tumor ratio for highly accurate ICI response prediction.
Researchers at UCLA have successfully created a continuous supply of functional T cells using genetically engineered stem cells. This breakthrough could lead to longer-lasting protection against cancer and potentially treat other diseases such as HIV or autoimmune disorders.
Emerging technologies like spatial and single-cell omics improve our understanding of tumor biology and facilitate personalized cancer immunotherapies. These approaches enable researchers to identify novel biomarkers that predict therapeutic responses and monitor disease progression in real-time, ultimately improving patient outcomes.
Researchers have developed a novel synthetic ligand using AI-based computational protein design, activating the Notch signaling pathway in T-cells. This breakthrough enables broadened clinical T-cell production and advances immunotherapy development.
A study of ovarian tumor immune landscapes reveals four distinct immunologic subtypes, with those with T cells surviving longer and having better outcomes. The researchers also found that myeloid cells play a key role in reestablishing the immune landscape upon recurrence.
This meta-analysis found that FMT combined with ICIs resulted in improved objective response and disease control rates, with an acceptable safety profile. Subgroup analysis revealed a significant association between the combination of anti-PD-1 and anti-CTLA-4 therapies and higher overall response rates.
A decade-long study reveals that the source of dietary fat, not adiposity itself, is the primary factor influencing tumor growth in obese mice. High-fat diets derived from animal fats compromise anti-tumor immunity and accelerate tumor growth, while plant-based fats have a neutral effect.
A recent study identified four genes associated with treatment resistance to immunotherapy in melanoma patients. The genes, CD24, NFIL3, FN1, and KLRK1, were found to be linked to mechanisms of immune evasion and suppression of the inflammatory response. Patients with high expression of these genes had significantly lower overall survi...
Researchers discovered that a type of HPV commonly found on the skin can directly cause a form of skin cancer called cutaneous squamous cell carcinoma when immune cells malfunction. The study's findings suggest that other people with defective T-cell responses may also be susceptible to cancer caused directly by beta-HPV.
A new study shows that delivering a single injection of gene therapy at birth may offer years-long protection against HIV. The treatment uses an adeno-associated virus to deliver instructions to muscle cells, which produce broadly neutralizing antibodies capable of neutralizing multiple strains of HIV.
Researchers at UC San Diego School of Medicine have developed a novel approach to enhance the effectiveness of immunotherapy treatments for head and neck squamous cell carcinomas (HNSCC). Delivering radiation therapy that preserves tumor-draining lymph nodes followed by immunotherapy resulted in a complete and durable tumor response in...
Researchers discovered a way to boost T cells' ability to fight cancer by rewiring their energy metabolism. By blocking Ant2 protein, they created a state of heightened readiness and potency in T cells, leading to greater stamina, faster replication, and sharper targeting of cancerous threats.
Diana Hargreaves will receive $1 million to advance her project on improving immunotherapy in patients with pancreatic cancer. Her previous work identified better drug targets for cancers with SWI/SNF mutations, leading to breakthroughs in treating difficult-to-treat cancers.
Researchers propose a synergistic combination strategy using systemic type I interferons (IFN-I) and local TLR7/8 agonists to enhance dendritic cell activation and inhibit metastatic tumors. This approach enhances early innate immune control and later induces CD8+ T cell responses.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
Researchers identified key factors behind a successful immunotherapy response in a young patient with rhabdoid tumour. The study highlights the potential of sequencing technologies to track immune cell profiles and develops personalized cell therapies.
Researchers from Korea University have discovered that the protein WEE1 can paradoxically drive immune resistance in cancer cells when located in the cytoplasm. This study suggests that targeting WEE1 with an inhibitor, such as adavosertib, may sensitize tumors to immunotherapy and reinvigorate antitumor immunity.
Researchers from Memorial Sloan Kettering Cancer Center developed a new approach to induce mutations in resistant cancer cells, making them sensitive to immunotherapy. The study showed positive outcomes in patients over 90 with lung cancer who underwent surgery.
A Phase II study found that 87% of patients with stage III melanoma remained alive and disease-free four years after treatment with nivolumab and relatlimab. Researchers identified unique biomarkers associated with better outcomes, including high TIGIT levels and low B7-H3 levels.
A retrospective study found teclistamab-cqyv to be effective in patients with high-risk, heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial. The bispecific antibody reduced disease burden by at least half in 53% of evaluable patients, and 45% achieved a 'very good partial response'. Despite a hi...
A new study from the University of Pittsburgh shows exercise improves cancer outcomes and enhances response to immunotherapy in mice by reshaping the gut microbiome. The research found that a specific compound called formate, produced by gut bacteria in exercised mice, was associated with better outcomes in patients with melanoma.
CD8⁺ T cell exhaustion is the silent saboteur of immune destruction, caused by chronic antigen exposure, immune suppressor cells, and epigenetic shifts. Next-generation interventions like CAR-T engineering and CRISPR-based reprogramming promise to restore immune vigor.
A new dual CAR-T cell therapy has been developed to target T-ALL, showing high efficacy and safety. The treatment targets two antigens simultaneously, making it more effective than previous therapies. Experimental results demonstrate its ability to control the disease in both laboratory and animal models, with an excellent safety profile.
Researchers develop self-assembling nanoparticles that induce ferroptosis in bladder cancer cells while reprogramming the tumor immune microenvironment, boosting anti-tumor activity. The nanomedicine has dual functions as a multifaceted approach to overcome treatment resistance and is Clinically translatable.
Researchers have discovered that blocking NK cell checkpoints could significantly enhance cancer immunotherapy, providing new avenues for treating solid tumors and blood cancers. Emerging precision approaches using gene editing and engineered cell therapies promise specific recognition of cancer cells with potentially fewer side effects.
A new dual-phase CT AI tool, NeoPred, combines pre-treatment and pre-surgery scans with clinical data to predict major pathological response in NSCLC patients. The model achieved high accuracy rates, including AUCs of 0.772-0.787, outperforming surgeons and improving diagnostic accuracy.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
The BRACELET-1 trial demonstrated a 20% objective response rate and 12.1-month progression-free survival for patients with unresectable HR+ HER2- tumors, suggesting that adding pelareorep to paclitaxel chemotherapy warrants further investigation in metastatic breast cancer.
A new review identifies CHEK2 as a potential biomarker for predicting response to immunotherapy and suggests that combining CHEK2 inhibitors with existing therapies may enhance anti-tumor effects. This could lead to improved treatment outcomes in solid tumors.
The addition of perioperative toripalimab to platinum-based chemotherapy has demonstrated significant improvements in disease-related outcomes, including event-free survival and major pathologic response rates. However, this is associated with a small increase in grade 3–5 toxicities and immune-related adverse events.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Researchers found that using Tumor Treating Fields therapy (TTFields) combined with immunotherapy (pembrolizumab) and chemotherapy (temozolomide) may extend survival for glioblastoma patients. TTFields disrupt tumor growth, attracting more immune cells to attack cancerous cells.
Researchers identified a link between the loss of Y chromosome in white blood cells and reduced ability to kill cancer cells. This finding may explain why men with loss of Y have higher cancer risks and poorer outcomes. The study provides insights into how this genetic change affects immune system function.
The study identified key proteins and signaling pathways involved in CAR-T cell therapy's efficacy, including cytokines, kinases, receptors, proteases, and chemical messengers. The findings pave the way for new treatment advances and potential biomarkers.
A phase 2 trial found that combining avelumab and cetuximab significantly extended median progression-free survival in patients with advanced cutaneous squamous cell carcinoma. The combination showed synergistic effects, suggesting a potential new standard of care for this patient population.
Researchers have uncovered a key reason why HIV remains difficult to cure, revealing that subtle variations in the Rev-RRE axis influence viral replication and latency reactivation. Understanding this regulatory system could help develop strategies to flush out the dormant virus and eliminate it for good.
Dr. Natalie Artzi joins the Wyss Institute as Associate Institute Director, working closely with Don Ingber to shape strategic direction and advance research and translation efforts. She leads a world-class research program focused on developing tissue- and cell-responsive nanostructures for disease tracking and treatment.
Researchers at Memorial Sloan Kettering Cancer Center have discovered that Bacillus Calmette-Guérin (BCG) therapy reprograms and amplifies cells in the bone marrow, enhancing the innate immune system's ability to combat cancer. This breakthrough could lead to improved immunotherapies for various cancers.